Search results for "Pharmacology. Therapy"

showing 10 items of 30 documents

Prenylated Flavonoids from the Roots of Tephrosia rhodesica

2020

Five new compounds—rhodimer (1), rhodiflavan A (2), rhodiflavan B (3), rhodiflavan C (4), and rhodacarpin (5)—along with 16 known secondary metabolites, were isolated from the CH2Cl2–CH3OH (1:1) extract of the roots of Tephrosia rhodesica. They were identified by NMR spectroscopic, mass spectrometric, X-ray crystallographic, and ECD spectroscopic analyses. The crude extract and the isolated compounds 2–5, 9, 15, and 21 showed activity (100% at 10 μg and IC50 = 5–15 μM) against the chloroquine-sensitive (3D7) strain of Plasmodium falciparum. peerReviewed

Plasmodium falciparumPharmaceutical Sciencemolecular structurehernekasvitCrystallography X-Ray01 natural sciencesPlant RootsArticleAnalytical ChemistryAntimalarialsflavonoiditPrenylationDrug DiscoveryBiological sciencesBiologynuclear magnetic resonance spectroscopyPharmacologyFlavonoidsPrenylationantimikrobiset yhdisteetOrganisk kemiChromatographybiologyStrain (chemistry)Molecular Structure010405 organic chemistryTephrosiaChemistrySpectrum AnalysisPharmacology. TherapycarbonOrganic ChemistryPlasmodium falciparumbiology.organism_classificationcircular dichroism spectroscopyluonnonaineetMass spectrometric0104 chemical sciences010404 medicinal & biomolecular chemistryChemistryComplementary and alternative medicineTephrosiaMolecular MedicineSpectrum analysismetabolism
researchProduct

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

2015

Abstract: Introduction: Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation. In advanced non-small cell lung cancer (NSCLC), the recognition of oncogenic activation of specific RTKs, has led to the development of molecularly targeted agents that only benefit roughly 20% of patients. Entrectinib is a pan-TRK, ROS1 and ALK inhibitor that has shown potent anti-neoplastic activity and tolerability in various neoplastic conditions, particularly NSCLC. Areas covered: This review outlines the pharmacokinetics, pharmacodynamics, mechanism of action, safety, tolerability, pre-cl…

Receptor Protein-Tyrosine KinasesEntrectinibNTRK1NTRK2NTRK3Receptor tyrosine kinaseEntrectinibMalignant transformationAntineoplastic AgentNeoplasmsProtein-Tyrosine KinaseALK; colorectal cancer; Entrectinib; non-small cell lung cancer; NTRK1; NTRK2; NTRK3; precision medicine; ROS1; salivary gland cancer; TrkA; TrkB; TrkC; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor; trkA; Receptor; trkB; Receptor; trkC; Pharmacology; Pharmacology (medical)Anaplastic Lymphoma KinasePharmacology (medical)salivary gland cancerProto-Oncogene ProteinbiologyTrkAPharmacology. TherapyTrkCTrkBGeneral MedicineProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinaseBenzamidesmedicine.symptomROS1ReceptorHumanIndazolesmedicine.drug_classprecision medicineAntineoplastic Agentscolorectal cancerBenzamideProto-Oncogene ProteinsmedicineROS1AnimalsHumansReceptor trkBReceptor trkCReceptor trkAnon-small cell lung cancerPharmacologyAnimalReceptor Protein-Tyrosine KinasesALK inhibitorIndazoleMechanism of actionALKTrk receptorbiology.proteinCancer researchNeoplasmALK; colorectal cancer; Entrectinib; non-small cell lung cancer; NTRK1; NTRK2; NTRK3; precision medicine; ROS1; salivary gland cancer; TrkA; TrkB; TrkC; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor trkA; Receptor trkB; Receptor trkC; Pharmacology; Pharmacology (medical)Expert Opinion on Investigational Drugs
researchProduct

Spatio‐temporal assessment of illicit drug use at large scale : evidence from 7 years of international wastewater monitoring

2019

Background and aims Wastewater‐based epidemiology is an additional indicator of drug use that is gaining reliability to complement the current established panel of indicators. The aims of this study were to: (i) assess spatial and temporal trends of population‐normalized mass loads of benzoylecgonine, amphetamine, methamphetamine and 3,4‐methylenedioxymethamphetamine (MDMA) in raw wastewater over 7 years (2011–17); (ii) address overall drug use by estimating the average number of combined doses consumed per day in each city; and (iii) compare these with existing prevalence and seizure data. Design Analysis of daily raw wastewater composite samples collected over 1 week per year from 2011 to…

Research ReportWastewater‐based epidemiologyEcstasy/MDMAEpidemiologymedicine.medical_treatmentEcstasyPopulationIllicit drugs030508 substance abuseMedicine (miscellaneous)Wastewater-based epidemiology580 Plants (Botany)Methamphetamine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCocaineEnvironmental healthAmphetamine ; cocaine ; ecstasy ; MDMA ; illicit drugs ; methamphetamine ; wastewater-based epidemiologyIllicit drugMedicine030212 general & internal medicineeducationAmphetaminewastewater‐based epidemiologyeducation.field_of_studybusiness.industryPharmacology. TherapyMDMAResearch ReportsMethamphetamine6. Clean water3. Good healthStimulantPsychiatry and Mental healthInterdisciplinary Natural SciencesAmphetaminechemistryWastewaterMedicine (miscellaneous); Psychiatry and Mental healthEnvironmental ScienceBenzoylecgonine0305 other medical sciencebusinessmedicine.drugAddiction
researchProduct

BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.

2013

Abstract: Introduction: Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy. Areas covered: Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors p…

SorafenibIndolesLung NeoplasmsBevacizumabSettore MED/06 - Oncologia MedicaAngiogenesis InhibitorsPharmacologyVandetanibMetastasischemistry.chemical_compoundCarcinoma Non-Small-Cell LungmedicineAnimalsHumansPharmacology (medical)Lung cancerProtein Kinase InhibitorsPharmacologyNeovascularization Pathologicbusiness.industrySunitinibPharmacology. Therapyanti-angiogenesis BIBF 1120 nintedanib non-small cell lung cancer vascular endothelial growth factorGeneral MedicineProtein-Tyrosine Kinasesmedicine.diseaseVascular endothelial growth factorchemistryCancer researchNintedanibbusinessmedicine.drugExpert opinion on investigational drugs
researchProduct

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

2015

Abstract: Introduction: Angiogenesis is fundamental for tumor development and progression. Hence, anti-angiogenic drugs have been developed to target VEGF and its receptors (VEGFRs). Several tyrosine kinase inhibitors (TKIs) have been developed over the years and others are still under investigation, each anti-VEGFR TKI showing a different cardiotoxic profile. Knowledge of the cardiac side-effects of each drug and the magnitude of their expression and frequency can lead to a specific approach. Areas covered: This work reviews the mechanism of action of anti-VEGFR TKIs and the pathophysiological mechanisms leading to cardiotoxicity, followed by close examination of the most important drugs i…

SorafenibOncologymedicine.medical_specialtymedicine.drug_classSettore MED/06 - Oncologia MedicaAntineoplastic AgentsPharmacologyVandetanibModels BiologicalTyrosine-kinase inhibitorPazopanibchemistry.chemical_compoundInternal medicineRegorafenibNeoplasmsmedicineHumansPharmacology (medical)Molecular Targeted TherapyProtein Kinase Inhibitorstyrosine kinase inhibitor cardiac toxicityNeovascularization PathologicSunitinibbusiness.industryPharmacology. TherapyCancerHeartGeneral MedicineDrugs InvestigationalProtein-Tyrosine Kinasesmedicine.diseaseAxitinibReceptors Vascular Endothelial Growth FactorchemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

2016

Seuls les 100 premiers auteurs dont les auteurs INRA ont été entrés dans la notice. La liste complète des auteurs et de leurs affiliations est accessible sur la publication.; International audience; In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues…

[SDV]Life Sciences [q-bio]autophagosomeReview Articleddc:616.07stressstreLC3MESH: AnimalsSettore MED/49 - Scienze Tecniche Dietetiche ApplicateSettore BIO/06 - Anatomia Comparata E Citologiachaperone-mediated autophagyComputingMilieux_MISCELLANEOUSSettore BIO/11Pharmacology. TherapySettore BIO/13standards [Biological Assay]autolysosomeMESH: Autophagy*/physiologylysosomemethods [Biological Assay]Biological AssaySettore BIO/17 - ISTOLOGIAErratumHumanBiochemistry & Molecular BiologySettore BIO/06physiology [Autophagy]Chaperonemediated autophagy[SDV.BC]Life Sciences [q-bio]/Cellular BiologyNOautophagy guidelines molecular biology ultrastructureautolysosome; autophagosome; chaperone-mediated autophagy; flux; LC3; lysosome; macroautophagy; phagophore; stress; vacuoleMESH: Biological Assay/methodsMESH: Computer Simulationddc:570Autolysosome Autophagosome Chaperonemediated autophagy Flux LC3 Lysosome Macroautophagy Phagophore Stress VacuoleAutophagyAnimalsHumansComputer SimulationSettore BIO/10ddc:612BiologyphagophoreMESH: HumansvacuoleAnimalLC3; autolysosome; autophagosome; chaperone-mediated autophagy; flux; lysosome; macroautophagy; phagophore; stress; vacuole; Animals; Biological Assay; Computer Simulation; Humans; Autophagy0601 Biochemistry And Cell BiologyfluxmacroautophagyMESH: Biological Assay/standards*Human medicineLC3; autolysosome; autophagosome; chaperone-mediated autophagy; flux; lysosome; macroautophagy; phagophore; stress; vacuole
researchProduct

Conditioned Pain Modulation Is Not Impaired in Individuals with Frozen Shoulder: A Case-Control Study

2021

Frozen shoulder (FS) is a poorly understood condition resulting in substantial shoulder pain and mobility deficits. The mechanisms behind FS are not yet fully understood, but, similar to other persistent pain states, central pain mechanisms may contribute to ongoing symptoms in this population. The objective of this research was to investigate conditioned pain modulation (CPM) in people with FS compared with pain-free individuals. A total of 64 individuals with FS and 64 healthy volunteers participated in this cross-sectional study. CPM was assessed by using the pressure pain threshold (PPT) and an occlusion cuff (tourniquet test) as the test and conditioning stimulus, respectively. The abs…

assessmentHealth Toxicology and MutagenesisPopulationPainStimulus (physiology)ArticleBursitisOcclusionHumansconditioned pain modulationMedicinefrozen shouldereducationPain Measurementeducation.field_of_studybusiness.industryPharmacology. TherapyRPublic Health Environmental and Occupational HealthChronic painCase-control studyFrozen shoulderfrozen shoulder; conditioned pain modulation; inhibitory endogenous pain mechanisms; chronic pain; assessmentmedicine.diseaseCross-Sectional StudiesConditioned pain modulationCase-Control StudiesAnesthesiaMedicineTourniquet testHuman medicineinhibitory endogenous pain mechanismschronic painbusinessInternational Journal of Environmental Research and Public Health
researchProduct

Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?

2013

Abstract: Objective: miRNAs are attractive molecules for cancer treatment, including colon rectal cancer (CRC). We investigate on the molecular mechanism by which miR-182 could regulate thrombospondin-1 (TSP-1) expression, a protein down-regulated in CRC and inversely correlated with tumor vascularity and metastasis. Background: MicroRNAs are small non-coding RNAs that regulate the expression of different genes, involved in cancer progression, angiogenesis and metastasis. miR-182, over-expressed in colorectal cancer (CRC), has like predictive target thrombospondin-1 (TSP-1), a protein inversely correlated with tumor vascularity and metastasis that results downregulated in different types of…

endocrine systemPathologymedicine.medical_specialtyColorectal cancerAngiogenesisSettore MED/06 - Oncologia MedicaClinical BiochemistryEnzyme-Linked Immunosorbent AssayBiologyReal-Time Polymerase Chain ReactionMetastasisThrombospondin 1immune system diseasesCell Line TumorDrug DiscoverymicroRNAThrombospondin 1Sense (molecular biology)medicineHumansPromoter Regions GeneticDNA PrimersPharmacologyBase SequencePharmacology. Therapyvirus diseasesCancerTransfectionOligonucleotides Antisensemedicine.diseaseMicroRNAsCancer researchanti-miR-182 colon cancer Egr-1 Sp-1 thrombospondin-1Molecular MedicineColorectal Neoplasms
researchProduct

The formation, properties and impact of secondary organic aerosol: Current and emerging issues

2009

Hallquist, M. Wenger, J. C. Baltensperger, U. Rudich, Y. Simpson, D. Claeys, M. Dommen, J. Donahue, N. M. George, C. Goldstein, A. H. Hamilton, J. F. Herrmann, H. Hoffmann, T. Iinuma, Y. Jang, M. Jenkin, M. E. Jimenez, J. L. Kiendler-Scharr, A. Maenhaut, W. McFiggans, G. Mentel, Th. F. Monod, A. Prevot, A. S. H. Seinfeld, J. H. Surratt, J. D. Szmigielski, R. Wildt, J.; Secondary organic aerosol (SOA) accounts for a significant fraction of ambient tropospheric aerosol and a detailed knowledge of the formation, properties and transformation of SOA is therefore required to evaluate its impact on atmospheric processes, climate and human health. The chemical and physical processes associated wit…

humic-like substancesAtmospheric Scienceenvironmental chamber data010504 meteorology & atmospheric sciences010501 environmental sciences01 natural sciencessupercritical-fluid extractionlcsh:Chemistrychemistry.chemical_compoundHuman healthddc:550catalyzed heterogeneous reactionsProcess engineeringairborne particulate matter0105 earth and related environmental sciencesTropospheric aerosolpolycyclic aromatic-hydrocarbonsinitiated atmospheric oxidationAtmospheric modelsbusiness.industryPharmacology. Therapy[CHIM.CATA] Chemical Sciences/Catalysis[CHIM.CATA]Chemical Sciences/Catalysischromatography-mass spectrometrylcsh:QC1-999JAerosolChemistrylcsh:QD1-999chemistry13. Climate actionEnvironmental chemistryEarth and Environmental Scienceslow-molecular-weightAerosol mass spectrometrytropospheric chemistry mechanismOrganic componentCurrent (fluid)/dk/atira/pure/subjectarea/asjc/1900/1902businesslcsh:PhysicsOrganosulfate
researchProduct

In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Inje…

2021

This study evaluated in vitro and in vivo drug release of bedaquiline from in situ forming gels (ISGs) containing 200 mg eq./g bedaquiline fumarate salt prepared with four different grades of poly(d,l-lactide) (PDLLA) or poly(d,l-lactide-co-glycolide) (PLGA) with a lactide/glycolide ratio of 50/50 or 75/25 and acid (A) or ester (E) end-capping in N-methyl-2-pyrrolidone at a polymer/solvent ratio of 20/80% (w/w). Mean in vitro drug release in 0.05 M phosphate buffer pH 7.4 with 1% (w/v) sodium lauryl sulphate was 37.3, 47.1, 53.3, and 62.3% within 28 days for ISGs containing PLGA5050A, PDLLA, PLGA7525A, and PLGA7525E, respectively. The data suggested that drug release was primarily controlle…

porosityBedaquilinein vitro releasePharmaceutical SciencedissolutionPolyethylene glycolArticleDiffusionchemistry.chemical_compoundSubcutaneous injectionPharmacy and materia medicaPharmacokineticsIn vivoPharmacokineticsin situ forming gelsSolubilitybedaquilinesustained releaseinjectableLactidepolymer erosionPharmacology. TherapydiffusionIn vitro releasePolymer erosionRS1-441PLGAInjectablechemistryIn situ forming gelsBedaquilinePorositypharmacokineticsDissolutionNuclear chemistrySustained releasePharmaceutics
researchProduct